- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 176161-24-3] Maribavir
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16305 |
| Brand: | MCE |
| CAS: | 176161-24-3 |
Overview
| MDL | MFCD00945570 |
|---|---|
| Molecular Weight | 376.24 |
| Molecular Formula | C15H19Cl2N3O4 |
| SMILES | ClC1=C(Cl)C=C2C(N=C(NC(C)C)N2[C@@H]3[C@@H](O)[C@@H](O)[C@H](CO)O3)=C1 |
7 Publications Citing Use of MCE
Summary
Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC 50 of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus ( EBV ).
IC50 & Target
HCMV [1]
In Vitro
Maribavir is a potent inhibitor of the autophosporylation of the wild type and all the major Ganciclovir (GCV) resistant UL97 mutants analysed with a mean IC 50 of 35 nM. The M460I mutation results in hypersensitivity to Maribavir with an IC 50 of 4.8 nM. A Maribavir resistant mutant of UL97 (L397R) is functionally compromised as both a Ganciclovir kinase and a protein kinase (~ 10% of wild type levels). Enzyme kinetic experiments demonstrate that Maribavir is a competitive inhibitor of ATP with a K i of 10 nM [1] . Maribavir (1263W94) inhibits viral replication in a dose-dependent manner, with IC 50 of 0.12±0.01 μM as measured by a multicycle DNA hybridization assay. The pUL97 protein kinase is strongly inhibited by Maribavir, with 50% inhibition occurring at 3 nM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04131556 | Shire|Takeda |
Healthy Volunteers
|
October 25, 2019 | Phase 1 |
| NCT04497883 | Shire|Takeda |
Healthy Volunteers
|
August 7, 2020 | Phase 1 |
| NCT01611974 | Shire|Takeda |
Cytomegalovirus (CMV)
|
July 17, 2012 | Phase 2 |
| NCT05319353 | Takeda|Takeda Development Center Americas, Inc. |
Cytomegalovirus (CMV)
|
March 31, 2023 | Phase 3 |
| NCT00223925 | Shire|Takeda |
Cytomegalovirus Infection
|
October 28, 2004 | Phase 2 |
| NCT02927067 | Shire|Takeda Development Center Americas, Inc.|Takeda |
Cytomegalovirus (CMV)
|
April 14, 2017 | Phase 3 |
| NCT05382104 | Takeda|Takeda Development Center Americas, Inc. |
Healthy Volunteers
|
June 1, 2022 | Phase 1 |
| NCT02775240 | Shire|Takeda |
Cytomegalovirus (CMV)
|
July 21, 2016 | Phase 1 |
| NCT02931539 | Shire|Takeda |
Cytomegalovirus (CMV)
|
December 22, 2016 | Phase 3 |
| NCT00002373 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Infections|HIV Infections
|
Phase 1 | |
| NCT05137717 | Takeda |
Cytomegalovirus (CMV)
|
December 23, 2021 | Phase 3 |
| NCT00497796 | Shire|Takeda |
Cytomegalovirus Infections
|
July 23, 2007 | Phase 3 |
| NCT00411645 | Shire|Takeda |
Cytomegalovirus Infections
|
December 13, 2006 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 200 mg/mL ( 531.58 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6579 mL | 13.2894 mL | 26.5788 mL |
| 5 mM | 0.5316 mL | 2.6579 mL | 5.3158 mL |
| 10 mM | 0.2658 mL | 1.3289 mL | 2.6579 mL |
-
1.
-
2.
Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.87 mg/mL (7.63 mM); Clear solution
-
3.
-
4.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
-
5.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
References
- [1] Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4.
- [2] Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.